Little House Capital LLC Raises Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Little House Capital LLC increased its stake in Bristol Myers Squibb Company by 31.6% in the second quarter, now owning 25,028 shares valued at approximately $1.16 million.
• Several institutional investors have also adjusted their positions in Bristol Myers Squibb, contributing to 76.41% of the company's stock being held by such investors.
• Bristol Myers Squibb reported an earnings per share of $1.46 for the last quarter, surpassing consensus estimates and reflecting a revenue increase of 0.6% compared to the previous year.

Little House Capital LLC grew its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 31.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,028 shares of the biopharmaceutical company's stock after purchasing an additional 6,009 shares during the quarter. Little House Capital LLC's holdings in Bristol Myers Squibb were worth $1,159,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. New England Asset Management Inc. lifted its position in Bristol Myers Squibb by 0.8% during the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock valued at $2,408,000 after buying an additional 305 shares during the period. Commonwealth Equity Services LLC grew its stake in shares of Bristol Myers Squibb by 1.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company's stock valued at $78,580,000 after purchasing an additional 13,959 shares during the period. Avaii Wealth Management LLC grew its stake in shares of Bristol Myers Squibb by 590.9% during the 1st quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock valued at $4,794,000 after purchasing an additional 67,221 shares during the period. Ransom Advisory Ltd bought a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at about $843,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of Bristol Myers Squibb by 1.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock valued at $3,967,000 after buying an additional 869 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BMY shares. Daiwa America cut Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Citigroup lowered their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday, August 1st. Finally, Daiwa Capital Markets cut Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $46.34 on Tuesday. The company has a market cap of $94.32 billion, a P/E ratio of 18.69, a P/E/G ratio of 2.36 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The business's 50 day moving average price is $47.07 and its 200-day moving average price is $49.98. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.07% of the stock is owned by company insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.